Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican Children

BMC Immunology

Carlota Dobaño⁵  Clara Menéndez⁵  Pedro L Alonso⁵  Denise L Doolan³  John J Aponte⁵  Sergi Sanz⁵  Pedro Aide⁴  Eusébio Macete²  Elisa Serra-Casas⁵  Tacilta Nhampossa⁴  Llorenç Quintó⁵  Laura Puyol⁵  Diana Quelhas¹ 

[1]Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique

[2]Direcção Nacional de Saúde, Ministério da Saúde, Maputo, Mozambique

[3]Queensland Institute of Medical Research (QIMR), Brisbane, Australia

[4]Instituto Nacional de Saúde, Ministério da Saúde, Maputo, Mozambique

[5]Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, Universitat de Barcelona, Spain

关键词: sulfadoxine-pyrimethamine;    falciparum malaria;    IPTi;    chemokines;    cytokines;   

Others  :  1077945
DOI  :  10.1186/1471-2172-13-5

 received in 2011-09-08, accepted in 2012-01-26,  发布年份 2012

【 摘 要 】

Background

Cytokines and chemokines are key mediators of anti-malarial immunity. We evaluated whether Intermittent Preventive Treatment in infants with Sulfadoxine-Pyrimethamine (IPTi-SP) had an effect on the acquisition of these cellular immune responses in Mozambican children. Multiple cytokines and chemokines were quantified in plasma by luminex, and antigen-specific cytokine production in whole blood was determined by intracellular cytokine staining and flow cytometry, at ages 5, 9, 12 and 24 months.

Results

IPTi-SP did not significantly affect the proportion of CD3+ cells producing IFN-γ, IL-4 or IL-10. Overall, plasma cytokine or chemokine concentrations did not differ between treatment groups. Th1 and pro-inflammatory responses were higher than Th2 and anti-inflammatory responses, respectively, and IFN-γ:IL-4 ratios were higher for placebo than for SP recipients. Levels of cytokines and chemokines varied according to age, declining from 5 to 9 months. Plasma concentrations of IL-10, IL-12 and IL-13 were associated with current infection or prior malaria episodes. Higher frequencies of IFN-γ and IL-10 producing CD3+ cells and elevated IL-10, IFN-γ, MCP-1 and IL-13 in plasma were individually associated with increased malaria incidence, at different time points. When all markers were analyzed together, only higher IL-17 at 12 months was associated with lower incidence of malaria up to 24 months.

Conclusions

Our work has confirmed that IPTi-SP does not negatively affect the development of cellular immune response during early childhood. This study has also provided new insights as to how these cytokine responses are acquired upon age and exposure to P. falciparum, as well as their associations with malaria susceptibility.

Trial Registration

ClinicalTrials.gov: NCT00209795

【 授权许可】

   
2012 Quelhas et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: World Malaria Report 2010. 2010, 39-62.
• [2]Doolan DL, Dobaño C, Baird JK: Acquired immunity to malaria. Clinical Microbiology Reviews 2009, 22:13-36.
• [3]Marsh K: Malaria--a neglected disease? Parasitology 1992, 104(Suppl):S53-69.
• [4]Cohen S, McGregor IA, Carrington S: Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
• [5]Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, Anderson K, Mahakunkijcharoen Y, Martin LB, Wilson D, Elliott S, Eisen DP, Weinberg JB, Saul A, Good MF: Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
• [6]Good MF, Xu H, Wykes M, Engwerda CR: Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annual Review of Immunology 2005, 23:69-99.
• [7]Fritsche G, Larcher C, Schennach H, Weiss G: Regulatory interactions between iron and nitric oxide metabolism for immune defense against Plasmodium falciparum infection. The Journal of Infectious Diseases 2001, 183:1388-94.
• [8]Tsuji M, Rodrigues EG, Nussenzweig S: Progress toward a malaria vaccine: efficient induction of protective anti-malaria immunity. Biological Chemistry 2001, 382:553-70.
• [9]Ramharter M, Willheim M, Winkler H, Wahl K, Lagler H, Graninger W, Winkler S: Cytokine profile of Plasmodium falciparum-specific T cells in non-immune malaria patients. Parasite Immunology 2003, 25:211-219.
• [10]Luty AJ, Perkins DJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Weinberg JB, Kremsner PG: Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infection and Immunity 2000, 68:3909-15.
• [11]Perkins DJ, Weinberg JB, Kremsner PG: Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. The Journal of Infectious Diseases 2000, 182:988-992.
• [12]Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, Mai NT, Phu NH, Sinh DX, White NJ, Ho M: The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. The Journal of Infectious Diseases 1999, 180:1288-1297.
• [13]Brown H, Turner G, Rogerson S, Tembo M, Mwenechanya J, Molyneux M, Taylor T: Cytokine expression in the brain in human cerebral malaria. The Journal of Infectious Diseases 1999, 180:1742-6.
• [14]Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M: Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. The American Journal of Medicine 1989, 87:139-43.
• [15]Molyneux ME, Taylor TE, Wirima JJ, Grau GE: Tumour necrosis factor, interleukin-6, and malaria. Lancet 1991, 337:1098.
• [16]Grau GE, Piguet PF, Vassalli P, Lambert PH: Tumor-necrosis factor and other cytokines in cerebral malaria: experimental and clinical data. Immunological Reviews 1989, 112:49-70.
• [17]Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello CA, Greenwood BM: Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clinical and Experimental Immunology 1989, 77:361-6.
• [18]Kwiatkowski D, Hill AV, Sambou I, Twumasi P, Castracane J, Manogue KR, Cerami A, Brewster DR, Greenwood BM: TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990, 336:1201-4.
• [19]Körner H, McMorran B, Schlüter D, Fromm P: The role of TNF in parasitic diseases: Still more questions than answers. International Journal for Parasitology 2010, 40:879-88.
• [20]Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V: A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. The Journal of Infectious Diseases 1999, 179:279-282.
• [21]Scuderi P, Sterling KE, Lam KS, Finley PR, Ryan KJ, Ray CG, Petersen E, Slymen DJ, Salmon SE: Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986, 2:1364-5.
• [22]Shaffer N, Grau GE, Hedberg K, Davachi F, Lyamba B, Hightower AW, Breman JG, Phuc ND: Tumor necrosis factor and severe malaria. The Journal of Infectious Diseases 1991, 163:96-101.
• [23]Eisenhut M: The role of interleukin-4 in the immune response to Plasmodium falciparum. Parasite Immunology 2010, 32:470-471.
• [24]Kumaratilake LM, Ferrante A: IL-4 inhibits macrophage-mediated killing of Plasmodium falciparum in vitro. A possible parasite-immune evasion mechanism. Journal of Immunology 1992, 149:194-199.
• [25]Troye-Blomberg M: Human T-cell responses to blood stage antigens in Plasmodium falciparum malaria. Immunology Letters 1994, 41:103-107.
• [26]Kurtzhals JA, Adabayeri V, Goka BQ, Akanmori BD, Oliver-Commey JO, Nkrumah FK, Behr C, Hviid L: Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Lancet 1998, 351:1768-1772.
• [27]Winkler S, Willheim M, Baier K, Schmid D, Aichelburg A, Graninger W, Kremsner PG: Reciprocal regulation of Th1- and Th2-cytokine-producing T cells during clearance of parasitemia in Plasmodium falciparum malaria. Infection and Immunity 1998, 66:6040-4.
• [28]Ochiel DO, Awandare GA, Keller CC, Hittner JB, Kremsner PG, Weinberg JB, Perkins DJ: Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. Infection and Immunity 2005, 73:4190-7.
• [29]Perkins DJ, Kremsner PG, Weinberg JB: Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria. The Journal of Infectious Diseases 2001, 183:113-118.
• [30]Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM: Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. The Journal of Infectious Diseases 2002, 185:971-979.
• [31]Sedegah M, Finkelman F, Hoffman SL: Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:10700-2.
• [32]Torre D, Speranza F, Giola M, Matteelli A, Tambini R, Biondi G: Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. Clinical and Diagnostic Laboratory Immunology 2002, 9:348-51.
• [33]Chizzolini C, Grau GE, Geinoz A, Schrijvers D: T lymphocyte interferon-gamma production induced by Plasmodium falciparum antigen is high in recently infected non-immune and low in immune subjects. Clinical and Experimental Immunology 1990, 79:95-9.
• [34]Harpaz R, Edelman R, Wasserman SS, Levine MM, Davis JR, Sztein MB: Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge. The Journal of Clinical Investigation 1992, 90:515-23.
• [35]Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Migot-Nabias F, Deloron P, Nussenzweig RS, Kremsner PG: Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. The Journal of Infectious Diseases 1999, 179:980-8.
• [36]Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B, Schönfeld HJ, Holder AA, Greenwood BM: Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunology 1992, 14:321-37.
• [37]Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P: Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. The Journal of Experimental Medicine 1995, 182:409-18.
• [38]John CC, Sumba PO, Ouma JH, Nahlen BL, King CL, Kazura JW: Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya. Infection and Immunity 2000, 68:5198-204.
• [39]Prakash D, Fesel C, Jain R, Cazenave PA, Mishra GC, Pied S: Clusters of cytokines determine malaria severity in Plasmodium falciparum-infected patients from endemic areas of Central India. The Journal of Infectious Diseases 2006, 194:198-207.
• [40]Deloron P, Lepers JP, Coulanges P: Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria. Journal of Clinical Microbiology 1989, 27:1887-9.
• [41]Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, Jansen-Rosseck R, Bienzle U: Immune response in patients during and after Plasmodium falciparum infection. The Journal of Infectious Diseases 1990, 161:1025-8.
• [42]Nguyen-Dinh P, Greenberg AE: Increased levels of released interleukin-2 receptors in Plasmodium falciparum malaria. The Journal of Infectious Diseases 1988, 158:1403-4.
• [43]Rhodes-Feuillette A, Bellosguardo M, Druilhe P, Ballet JJ, Chousterman S, Canivet M, Périès J: The interferon compartment of the immune response in human malaria: II. Presence of serum-interferon gamma following the acute attack. Journal of Interferon Research 1985, 5:169-78.
• [44]Peyron F, Vuillez JP, Barbe G, Boudin C, Picot S, Ambroise-Thomas P: Plasma levels of tumor necrosis factor during a longitudinal survey in an endemic area of malaria. Acta Tropica 1990, 47:47-51.
• [45]Riley EM, Morris-Jones S, Blackman MJ, Greenwood BM, Holder AA: A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunology 1993, 15:513-524.
• [46]Bouyou-Akotet MK, Kombila M, Kremsner PG, Mavoungou E: Cytokine profiles in peripheral, placental and cord blood in pregnant women from an area endemic for Plasmodium falciparum. European Cytokine Network 2004, 15:120-125.
• [47]Breitling LP, Fendel R, Mordmueller B, Adegnika AA, Kremsner PG, Luty AJF: Cord blood dendritic cell subsets in African newborns exposed to Plasmodium falciparum in utero. Infection and Immunity 2006, 74:5725-9.
• [48]Brustoski K, Kramer M, Möller U, Kremsner PG, Luty AJF: Neonatal and maternal immunological responses to conserved epitopes within the DBL-gamma3 chondroitin sulfate A-binding domain of Plasmodium falciparum erythrocyte membrane protein 1. Infection and Immunity 2005, 73:7988-95.
• [49]Brustoski K, Moller U, Kramer M, Hartgers FC, Kremsner PG, Krzych U, Luty AJF: Reduced cord blood immune effector-cell responsiveness mediated by CD4+ cells induced in utero as a consequence of placental Plasmodium falciparum infection. The Journal of Infectious Diseases 2006, 193:146-54.
• [50]Brustoski K, Moller U, Kramer M, Petelski A, Brenner S, Palmer DR, Bongartz M, Kremsner PG, Luty AJ, Krzych U: IFN-gamma and IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated Plasmodium falciparum malaria. Journal of Immunology 2005, 174:1738-1745.
• [51]Fievet N, Ringwald P, Bickii J, Dubois B, Maubert B, Le Hesran JY, Cot M, Deloron P: Malaria cellular immune responses in neonates from Cameroon. Parasite Immunology 1996, 18:483-90.
• [52]King CL, Malhotra I, Wamachi A, Kioko J, Mungai P, Wahab SA, Koech D, Zimmerman P, Ouma J, Kazura JW: Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. Journal of Immunology 2002, 168:356-64.
• [53]Malhotra I, Mungai P, Muchiri E, Ouma J, Sharma S, Kazura JW, King CL: Distinct Th1- and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands. Infection and Immunity 2005, 73:3462-3470.
• [54]Metenou S Jr, Long C, Leke RG, Taylor DW: Fetal Immune Responses to Plasmodium falciparum Antigens in a Malaria-Endemic Region of Cameroon. Journal of Immunology 2007, 178:2770-2777.
• [55]Hesran JYL, Fievet N, Thioulouse J, Personne P, Maubert B, M'bidias S, Etye'ale D, Cot M, Deloron P: Development of cellular immune responses to Plasmodium falciparum blood stage antigens from birth to 36 months of age in Cameroon. Acta Tropica 2006, 98:261-269.
• [56]Mshana RN, Boulandi J, Mshana NM, Mayombo J, Mendome G: Cytokines in the pathogenesis of malaria: levels of IL-I beta, IL-4, IL-6, TNF-alpha and IFN-gamma in plasma of healthy individuals and malaria patients in a holoendemic area. Journal of Clinical & Laboratory Immunology 1991, 34:131-9.
• [57]Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, Sigauque B, Dobaño C, Mabunda S, Dgedge M, Alonso P, Menendez C: Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in mozambican infants: a randomized, placebo-controlled trial. The Journal of Infectious Diseases 2006, 194:276-285.
• [58]Quelhas D, Jiménez A, Quintó L, Serra-Casas E, Mayor A, Cisteró P, Puyol L, Wilson D, Richards J, Nhampossa T, Macete E, Aide P, Mandomando I, Sanz S, Aponte J, Alonso P, Beeson J, Menéndez C, Dobaño C: IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with Sulfadoxine-Pyrimethamine. Immunobiology 2011, 216:793-802.
• [59]Quelhas D, Puyol L, Quinto L, Serra-Casas E, Nhampossa T, Macete E, Aide P, Mayor A, Mandomando I, Sanz S, Aponte JJ, Chauhan VS, Chitnis CE, Alonso PL, Menendez C, Dobaño C: Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clinical and Vaccine Immunology 2008, 15:1282-1291.
• [60]Otoo LN, Riley EM, Menon A, Byass P, Greenwood BM: Cellular immune responses to Plasmodium falciparum antigens in children receiving long term anti-malarial chemoprophylaxis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1989, 83:778-782.
• [61]Friedman JF, Phillips-Howard PA, Hawley WA, Terlouw DJ, Kolczak MS, Barber M, Okello N, Vulule JM, Duggan C, Nahlen BL, ter Kuile FO: Impact of permethrin-treated bed nets on growth, nutritional status, and body composition of primary school children in western Kenya. The American Journal of Tropical Medicine and Hygiene 2003, 68:78-85.
• [62]Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B: Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. The Lancet 2009, 374:1533-1542.
• [63]Barbosa A, Naniche D, Aponte JJ, Manaca MN, Mandomando I, Aide P, Sacarlal J, Renom M, Lafuente S, Ballou WR, Alonso PL: Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infection and Immunity 2009, 77:4502-4509.
• [64]Struik SS, Omer FM, Artavanis-Tsakonas K, Riley EM: Uninfected erythrocytes inhibit Plasmodium falciparum-induced cellular immune responses in whole-blood assays. Blood 2004, 103:3084-92.
• [65]Walther M, Woodruff J, Edele F, Jeffries D, Tongren JE, King E, Andrews L, Bejon P, Gilbert SC, Souza JBD, Sinden R, Hill AV, Riley EM: Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. Journal of Immunology 2006, 177:5736-5745.
• [66]Jason J, Archibald LK, Nwanyanwu OC, Byrd MG, Kazembe PN, Dobbie H, Jarvis WR: Comparison of serum and cell-specific cytokines in humans. Clinical and Diagnostic Laboratory Immunology 2001, 8:1097-1103.
• [67]Abacassamo F, Enosse S, Aponte JJ, Gomez-Olive FX, Quinto L, Mabunda S, Barreto A, Magnussen P, Ronn AM, Thompson R, Alonso PL: Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Tropical Medicine & International Health 2004, 9:200-208.
• [68]Saúte F, Aponte J, Almeda J, Ascaso C, Abellana R, Vaz N, Dgedge M, Alonso P: Malaria in southern Mozambique: malariometric indicators and malaria case definition in Manhiça district. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003, 97:661-6.
• [69]PrabhuDas M, Adkins B, Gans H, King C, Levy O, Ramilo O, Siegrist CA: Challenges in infant immunity: implications for responses to infection and vaccines. Nature Immunology 2011, 12:189-194.
• [70]van de Veerdonk FL, Gresnigt MS, Kullberg BJ, van der Meer JWM, Joosten LAB, Netea MG: Th17 responses and host defense against microorganisms: an overview. BMB Reports 2009, 42:776-87.
• [71]Hugosson E, Montgomery SM, Premji Z, Troye-Blomberg M, Bjorkman A: Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunology 2004, 26:111-117.
• [72]Troye-Blomberg M, Riley EM, Kabilan L, Holmberg M, Perlmann H, Andersson U, Heusser CH, Perlmann P: Production by activated human T cells of interleukin 4 but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:5484-5488.
• [73]McCall MBB, Sauerwein RW: Interferon-{gamma}--central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. Journal of Leukocyte Biology 2010, 88:1131-43.
• [74]Miller LH, Baruch DI, Marsh K, Doumbo OK: The pathogenic basis of malaria. Nature 2002, 415:673-679.
• [75]McCall MBB, Roestenberg M, Ploemen I, Teirlinck A, Hopman J, de Mast Q, Dolo A, Doumbo OK, Luty A, van der Ven AJAM, Hermsen CC, Sauerwein RW: Memory-like IFN-γ response by NK cells following malaria infection reveals the crucial role of T cells in NK cell activation by P. falciparum. European Journal of Immunology 2010, 40:3472-7.
• [76]Allison AC: Genetic control of resistance to human malaria. Current opinion in immunology 2009, 21:499-505.
• [77]Allison AC: Protection afforded by sickle-cell trait against subtertian malareal infection. British Medical Journal 1954, 1:290-4.
• [78]Aubouy A, Migot-Nabias F, Deloron P: Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria. Journal of molecular epidemiology and evolutionary genetics in infectious diseases 2007, 7:147-54.
• [79]Awandare GA, Ouma C, Keller CC, Were T, Otieno R, Ouma Y, Davenport GC, Hittner JB, Ong'echa JM, Ferrell R, Perkins DJ: A macrophage migration inhibitory factor promoter polymorphism is associated with high-density parasitemia in children with malaria. Genes and Immunity 2006, 7:568-75.
• [80]Basu M, Maji AK, Chakraborty A, Banerjee R, Mullick S, Saha P, Das S, Kanjilal SD, Sengupta S: Genetic association of Toll-like-receptor 4 and tumor necrosis factor-alpha polymorphisms with Plasmodium falciparum blood infection levels. Journal of molecular epidemiology and evolutionary genetics in infectious diseases 2010, 10:686-96.
• [81]Duah NO, Weiss HA, Jepson A, Tetteh KKA, Whittle HC, Conway DJ: Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigens. PloS One 2009, 4:e7381.
• [82]Hill AV: The immunogenetics of human infectious diseases. Annual Review of Immunology 1998, 16:593-617.
• [83]McNicholl JM, Downer MV, Udhayakumar V, Alper CA, Swerdlow DL: Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annual Review of Public Health 2000, 21:15-46.
• [84]Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, Otchwemah RN, Dietz E, Ehrhardt S, Schröder NWJ, Bienzle U, Schumann RR: Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:177-82.
• [85]Modiano D, Luoni G, Sirima BS, Lanfrancotti A, Petrarca V, Cruciani F, Simporé J, Ciminelli BM, Foglietta E, Grisanti P, Bianco I, Modiano G, Coluzzi M: The lower susceptibility to Plasmodium falciparum malaria of Fulani of Burkina Faso (west Africa) is associated with low frequencies of classic malaria-resistance genes. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001, 95:149-52.
• [86]Modiano D, Petrarca V, Sirima BS, Nebié I, Diallo D, Esposito F, Coluzzi M: Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:13206-11.
• [87]Ockenhouse CF, chung Hu W, Kester KE, Cummings JF, Stewart A, Heppner DG, Jedlicka AE, Scott AL, Wolfe ND, Vahey M, Burke DS: Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. Infection and Immunity 2006, 74:5561-73.
• [88]Paganotti GM, Palladino C, Modiano D, Sirima BS, Råberg L, Diarra A, Konaté A, Coluzzi M, Walliker D, Babiker HA: Genetic complexity and gametocyte production of Plasmodium falciparum in Fulani and Mossi communities in Burkina Faso. Parasitology 2006, 132:607-14.
• [89]Riley EM: The role of MHC- and non-MHC-associated genes in determining the human immune response to malaria antigens. Parasitology 1996, 112(Suppl):S39-51.
• [90]Stirnadel HA, Al-Yaman F, Genton B, Alpers MP, Smith TA: Assessment of different sources of variation in the antibody responses to specific malaria antigens in children in Papua New Guinea. International Journal of Epidemiology 2000, 29:579-86.
• [91]Traoré Y, Rihet P, Traoré-Leroux T, Aucan C, Gazin P, Coosemans M, Smith A, Abel L, Tall F, Nacro B, Traoré A, Fumoux F: Analysis of the genetic factors controlling malarial infection in man. Santé 1999, 9:53-9.
• [92]Mbugi EV, Meijerink M, Veenemans J, Jeurink PV, McCall M, Olomi RM, Shao JF, Chilongola JO, Verhoef H, Savelkoul HFJ: Effect of nutrient deficiencies on in vitro Th1 and Th2 cytokine response of peripheral blood mononuclear cells to Plasmodium falciparum infection. Malaria Journal 2010, 9:162. BioMed Central Full Text
• [93]Mbugi EV, Meijerink M, Veenemans J, Jeurink PV, McCall M, Olomi RM, Shao JF, Verhoef H, Savelkoul HF: Alterations in early cytokine-mediated immune responses to Plasmodium falciparum infection in Tanzanian children with mineral element deficiencies: a cross-sectional survey. Malaria Journal 2010, 9:130. BioMed Central Full Text
• [94]Chaisavaneeyakorn S, Moore JM, Otieno J, Chaiyaroj SC, Perkins DJ, Shi YP, Nahlen BL, Lal AA, Udhayakumar V: Immunity to placental malaria. III. Impairment of interleukin(IL)-12, not IL-18, and interferon-inducible protein-10 responses in the placental intervillous blood of human immunodeficiency virus/malaria-coinfected women. The Journal of Infectious Diseases 2002, 185:127-131.
• [95]Broen K, Brustoski K, Engelmann I, Luty AJF: Placental Plasmodium falciparum infection: causes and consequences of in utero sensitization to parasite antigens. Molecular and Biochemical Parasitology 2007, 151:1-8.